Shots:

• The P-III GRIPHON & P-IIIb TRITON trials evaluate Uptravi vs control group in 404 & 245 patients with PAH- respectively
• The results from a post-hoc pooled analysis showed a 52% reduction in the risk of disease progression @6mos.- Additionally- 48% reduction in the risk of disease progression among patients who received triple therapy group- AEs were consistent with the known safety profiles of Uptravi
• Uptravi (PO) is a selective- prostacyclin IP receptor agonist approved in the EU for PAH in adult patients with WHO FC II-III- either as combination therapy in patients insufficiently controlled with ERA & PDE5i- or as monothx. in patients who are temporarily unable to take oral therapies

  Ref: Businesswire | Image: Janssen